Verisante Technology has received the Conformite Europeenne (CE) mark for its Verisante Aura, used to diagnose skin cancers.

Aura is a non-invasive optical system used to identify suspected skin lesions for diagnosis as either skin cancer or a benign disorder within two seconds.

The move follows the six year clinical study at the Skin Care Centre at Vancouver General Hospital, British Columbia, where Verisante Aura was used to collect data on more than 1,000 lesions.

Vancouver General Hospital Skin Care Centre director Harvey Lui said Verisante Aura is a unique tool that can help doctors to detect skin cancers efficiently.

"With the rising incidence of all types of skin cancers, innovative tools such as the Aura, which can potentially be used by general practitioners to evaluate suspicious skin lesions quickly and accurately, will become increasingly important to the healthcare system," Lui added.

The company plans to launch the device in the EU region, Germany, Austria and Switzerland.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.